PMID- 38030311
OWN - NLM
STAT- MEDLINE
DCOM- 20231201
LR  - 20231217
IS  - 2352-3026 (Electronic)
IS  - 2352-3026 (Linking)
VI  - 10
IP  - 12
DP  - 2023 Dec
TI  - CD19-directed CAR T cells as first salvage therapy for large B-cell lymphoma: 
      towards a rational approach.
PG  - e1006-e1015
LID - S2352-3026(23)00307-1 [pii]
LID - 10.1016/S2352-3026(23)00307-1 [doi]
AB  - The approval of CD19-directed chimeric antigen receptor (CAR) T-cell therapies 
      for the second-line treatment of high-risk large B-cell lymphoma (LBCL) has 
      greatly affected salvage algorithms for this condition, and such therapies could 
      have the potential to improve the course of relapsed or refractory LBCL. In this 
      Review, we provide guidance for a rational management approach to the use of 
      commercial CD19-directed CAR T cells in the second-line treatment of LBCL, 
      addressing crucial questions regarding eligible histologies; age, comorbidity, 
      and tumour biology restrictions; the handling of very aggressive tumour 
      behaviour; and holding and bridging therapies. The guidance was developed in a 
      structured manner and, for each question, consists of a description of the 
      clinical issue, a summary of the evidence, the rationale for a practical 
      management approach, and recommendations. These recommendations could help to 
      decide on the optimal management of patients with relapsed or refractory LBCL who 
      are considered for second-line CAR T-cell treatment.
CI  - Copyright (c) 2023 Elsevier Ltd. All rights reserved.
FAU - Dreger, Peter
AU  - Dreger P
AD  - Department of Medicine V, University of Heidelberg, Heidelberg, Germany. 
      Electronic address: peter.dreger@med.uni-heidelberg.de.
FAU - Corradini, Paolo
AU  - Corradini P
AD  - Division of Hematology, IRCCS Istituto Nazionale dei Tumori Milano, University of 
      Milano, Milan, Italy.
FAU - Gribben, John G
AU  - Gribben JG
AD  - Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of 
      London, London, UK.
FAU - Glass, Bertram
AU  - Glass B
AD  - Department of Hematology and Cell Therapy, Helios Klinikum Berlin-Buch, Berlin, 
      Germany.
FAU - Jerkeman, Mats
AU  - Jerkeman M
AD  - Department of Oncology, Skane University Hospital, Lund, Sweden.
FAU - Kersten, Marie Jose
AU  - Kersten MJ
AD  - Department of Hematology, Amsterdam UMC, location AMC, Cancer Center Amsterdam 
      and LYMMCARE, Amsterdam, Netherlands.
FAU - Morschhauser, Franck
AU  - Morschhauser F
AD  - Hematology Department, CHU Lille, Universite de Lille, ULR 7365, Groupe de 
      Recherche sur les formes Injectables et les Technologies Associees, Lille, 
      France.
FAU - Mussetti, Alberto
AU  - Mussetti A
AD  - Hematology Department, Institut Catala d'Oncologia - Hospitalet, Institut 
      d'Investigacio Biomedique de Bellvitge, Universitat de Barcelona, Barcelona, 
      Spain.
FAU - Viardot, Andreas
AU  - Viardot A
AD  - Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany.
FAU - Zinzani, Pier Luigi
AU  - Zinzani PL
AD  - IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 
      "Seragnoli", Bologna, Italy; Dipartimento di Scienze Mediche e Chirurgiche, 
      Universita di Bologna, Bologna, Italy.
FAU - Sureda, Anna
AU  - Sureda A
AD  - Hematology Department, Institut Catala d'Oncologia - Hospitalet, Institut 
      d'Investigacio Biomedique de Bellvitge, Universitat de Barcelona, Barcelona, 
      Spain.
CN  - European Society for Blood and Marrow Transplantation and the European Hematology 
      Association Lymphoma Group
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Lancet Haematol
JT  - The Lancet. Haematology
JID - 101643584
RN  - 0 (Receptors, Antigen, T-Cell)
RN  - 0 (Antigens, CD19)
SB  - IM
MH  - Humans
MH  - *Receptors, Antigen, T-Cell/therapeutic use
MH  - Salvage Therapy
MH  - *Lymphoma, Large B-Cell, Diffuse/drug therapy
MH  - T-Lymphocytes
MH  - Immunotherapy, Adoptive
MH  - Antigens, CD19
COIS- Declaration of interests PC reports consultancy for BMS, Celgene, Gilead 
      Sciences, Janssen Pharmaceuticals, Novartis, Sanofi, and BeiGene; participation 
      on speakers' bureaus for BMS, Gilead Sciences, and Novartis; and travel grants 
      from Janssen Pharmaceuticals, Roche, Gilead Sciences, and Novartis. PD reports 
      consultancy for AbbVie, AstraZeneca, BeiGene, BMS, Gilead Sciences, Miltenyi 
      Biotec, Novartis, and Riemser; participation on speakers' bureaus for AbbVie, 
      AstraZeneca, BeiGene, BMS, Gilead Sciences, Novartis, Riemser, and Roche; and 
      research support from Riemser, all to his institution. BG reports consultancy for 
      BMS and Roche and research funding from Riemser. JGG reports consultancy for 
      AbbVie, Amgen, AstraZeneca, BMS/Celgene, Janssen Pharmaceuticals, Kite Gilead, 
      and Novartis; and research funding from AstraZeneca, BMS/Celgene, and Janssen 
      Pharmaceuticals. MJ reports consultancy for AbbVie, AstraZeneca, Autolus, Genmab, 
      Gilead Sciences, Janssen Pharmaceuticals, Novartis, Pierre Fabre, and Roche; and 
      research support from AbbVie, AstraZeneca, Gilead Sciences, Janssen 
      Pharmaceuticals, and Roche. MJK reports honoraria from BMS/Celgene, Kite/Gilead, 
      Novartis, and Roche; consulting or advisory roles for BMS/Celgene, Kite Gilead, 
      Miltenyi Biotec, Novartis, Takeda Pharmaceuticals, and Adicet Bio; and research 
      funding from Kite Gilead, all to her institution. FM reports consulting fees from 
      Roche, Gilead Sciences, Novartis, BMS, AbbVie, Genmab, Miltenyi Biotec, Allogene 
      Therapeutics, AstraZeneca, and Janssen Pharmaceuticals. AM reports consultancy 
      for BMS, Jazz Pharmaceuticals, Merck, and Takeda Pharmaceuticals; and research 
      funding from Kite Gilead. AS reports consultancy for BMS, Celgene, Gilead 
      Sciences, Janssen Pharmaceuticals, MSD, Novartis, Sanofi, and Takeda 
      Pharmaceuticals; participation on speakers' bureaus for BMS, MSD, and Takeda 
      Pharmaceuticals; and travel grants from BMS, Celgene, Janssen Pharmaceuticals, 
      Roche, Sanofi, and Takeda Pharmaceuticals. AV reports consultancy for AbbVie, 
      Gilead Sciences, Novartis, BMS, Roche, and Amgen; honoraria from Roche, Gilead 
      Sciences, BMS, and AbbVie; and travel grants from Roche, Gilead Sciences, and 
      AbbVie. PLZ reports consultancy for ADC Therapeutics, AstraZeneca, BeiGene, BMS, 
      Celltrion, EUSA Pharma, Incyte Kyowa Kirin, Novartis, Gilead Sciences, MSD, 
      Roche, Sandoz, Secura Bio, Servier Laboratories, and Takeda Pharmaceuticals; and 
      participation on speakers' bureaus for AstraZeneca, BeiGene, BMS, Celltrion, EUSA 
      Pharma, Incyte Kyowa Kirin, Novartis, Gilead Sciences, MSD, Roche, Servier 
      Laboratories, and Takeda Pharmaceuticals.
EDAT- 2023/11/30 00:42
MHDA- 2023/12/01 06:44
CRDT- 2023/11/29 20:56
PHST- 2023/04/21 00:00 [received]
PHST- 2023/09/09 00:00 [revised]
PHST- 2023/10/06 00:00 [accepted]
PHST- 2023/12/01 06:44 [medline]
PHST- 2023/11/30 00:42 [pubmed]
PHST- 2023/11/29 20:56 [entrez]
AID - S2352-3026(23)00307-1 [pii]
AID - 10.1016/S2352-3026(23)00307-1 [doi]
PST - ppublish
SO  - Lancet Haematol. 2023 Dec;10(12):e1006-e1015. doi: 10.1016/S2352-3026(23)00307-1.